Table 1. Baseline characteristics of studies included in the meta-analysis.
| Source | Intervention (dose, timing of first dose after surgery) |
Type of surgery | Surgery duration (minutes) | Use of neuraxial anaesthesia (%) | No. of patients | Mean age (years), female (%), mean weight (kg) | Day of venography | Follow up (days) | |
|---|---|---|---|---|---|---|---|---|---|
| Experimental group | Control group | ||||||||
| Eriksson 2006a | Rivaroxaban 2.5, 5, 10, 20, or 30 mg twice daily, 5–9 days (6–8 hours) | Enoxaparin 40 mg once daily, 5–9 days (about 12 hours*) | THA | 82 | 70 | 722 | 65, 59, 77 | 5–9 | 38–68 |
| Eriksson 2006b | Rivaroxaban 10, 20, or 30 mg once daily, 5–9 days (6–8 hours) | Enoxaparin 40 mg once daily, 5–9 days (about 12 hours*) | THA | 84 | 62 | 873 | 66, 64, 75 | 6–10 | 35–69 |
| Eriksson 2007 | Rivaroxaban 2.5, 5, 10, 20, or 30 mg twice daily, rivaroxaban 30 mg once daily, 5–9 days (6–8 hours) | Enoxaparin 40 mg once daily, 5–9 days (about 12 hours*) | THA | NA | 73 | 641 | 64, 54, 79 | 5–9 | 38–68 |
| Eriksson 2008 | Rivaroxaban 10 mg once daily, 35d (6–8 hours) | Enoxaparin 40 mg once daily, 35 days (about 12 hours*) | THA | 91 | 70 | 4541 | 63, 56, 78 | 36 | 66–71 |
| Kakkar 2008 | Rivaroxaban 10 mg once daily, 31–39 days (6–8 hours) | Enoxaparin 40 mg once daily, 14 days (about 12 hours*) +placebo 30 days | THA | 93 | 71 | 2509 | 62, 53, 75 | 32–40 | 62–75 |
| Lassen 2008 | Rivaroxaban 10 mg once daily, 10–14 days (6–8 hours) | Enoxaparin 40 mg once daily, 10–14 days (about 12 hours*) | TKA | 97 | 79 | 2531 | 68, 67, 81 | 11–15 | 41–50 |
| Turpie 2005 | Rivaroxaban 2.5, 5, 10, 20, or 30 mg twice daily, 5–9 days (6–8 hours) | Enoxaparin 30 mg twice daily, 5–9days (12–24 hours) | TKA | 91 | 53 | 621 | 66, 55, 89 | 5–9 | 37–67 |
| Turpie 2009 | Rivaroxaban 10 mg once daily, 10–14 days (6–8 hours) | Enoxaparin 30 mg twice daily, 10–14 days (12–24 hours) | TKA | 100 | 81 | 3148 | 65, 64, 84 | 11–15 | 40–49 |
| Zou 2014 | Rivaroxaban 10 mg once daily, 10–14 days (12 hours) | Enoxaparin 40 mg once daily, 14 days (12 hours) | TKA | 85 | 100% | 214 | 65, 76, NA | 8–14†, 22–28† | 28 |
THA: total hip arthroplasty; TKA: total knee arthroplasty; NA: not available.
*Administered preoperatively; other first doses were administered postoperatively.
†Color Doppler ultrasonography was performed.